Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study: Journal of Cutaneous Medicine and Surgery, Ahead of Print.
BackgroundSystemic therapy for atopic dermatitis (AD) has been challenging with limited safe and efficacious long-term treatment options. In 2017, dupilumab was approved in the United States, Europe, and Canada as the first targeted therapy for patients with moderate-to-severe AD. Despite promising efficacy and safety results in clinical trials, our understanding of dupilumab in clinical practice remains limited with few studies outside clinical trials in literature.ObjectiveThe aim of this study is to evaluate the efficacy and safety of dupilumab in clinical practice and discuss any differences in results between clinical trials and real-world results.MethodsA retrospective chart review was conducted of consecutive patients receiving dupilumab treatment at two tertiary hospitals in Toronto, Canada, between December 2017 and May 2019. The primary efficacy endpoint was measured by Investigator’s Global Assessment (IGA) score of 0/1 at 16 weeks and all adverse events (AEs) experienced by patients were recorded.ResultsOf the 93 patients included in the study, 51 (55%) reached IGA 0/1 and 38 (41%) experienced ≥1 AE. There were no severe AEs or discontinuation prior to 16 weeks due to an AE.ConclusionsThese findings suggest a higher IGA-based efficacy profile with no newly identified safety concerns in patients treated with dupilumab at two tertiary hospitals in Toronto, Canada, compared to those in randomized controlled trials.
Αρχειοθήκη ιστολογίου
-
►
2023
(269)
- ► Φεβρουαρίου (133)
- ► Ιανουαρίου (136)
-
►
2022
(2046)
- ► Δεκεμβρίου (165)
- ► Σεπτεμβρίου (161)
- ► Φεβρουαρίου (165)
-
►
2021
(3028)
- ► Δεκεμβρίου (135)
- ► Σεπτεμβρίου (182)
- ► Φεβρουαρίου (324)
-
▼
2020
(1051)
- ► Δεκεμβρίου (292)
- ► Σεπτεμβρίου (60)
-
▼
Μαΐου
(73)
-
▼
Μαΐ 28
(52)
- Medicine by Alexandros G. Sfakianakis,Anapafseos 5...
- The Diagnostic and Clinical Significance of TFE3 I...
- Primary Amoebic Meningoencephalitis from Recreatio...
- How to reduce the potential harmful effects o...
- Use of low-level laser therapy (LLLT) or photobiom...
- Blood Ties The expansive window of the ICU r...
- Eucaloric Very-Low-Carbohydrate Ketogenic Die...
- Acute-on-Chronic Liver Failure New England J...
- Resistance of children to Covi
- BioMed Research International
- Page 1 Select search result to email or save 1 C...
- 100 Eur Arch Otorhinolaryngol . 2020 May 25. doi:...
- Transnasal Prelacrimal Approach to the Inferio...
- Sinonasal Mucoepidermoid Carcinoma: A Review o...
- Clinical Characteristics of Acinic Cell Carcin...
- The New England Journal of Medicine: Search R...
- Angewandte Chemie International Edition,
- Evaluation of Subtotal Petrosectomy Technique in D...
- Patient-specific multi-omics models and the a...
- Hereditary Parathyroid Disease: Sometimes Patholog...
- Cancer
- Preoperative oral pregabalin for anxiety control: ...
- Annals of Neurology
- Squamous Cell Carcinoma Arising from Sinonasal Inv...
- Neck Imaging Reporting and Data System: Lexicon of...
- Nilotinib Effects on Safety, Tolerability, and Bio...
- SAGE-Journals: Journal of Cutaneous Medicine ...
- Identification of Novel Candidate Biomarkers for O...
- Identification of Novel Candidate Biomarkers for O...
- Short-Term Evaluation of the Real-World Efficacy a...
- Short-Term Evaluation of the Real-World Efficacy a...
- Vaccines
- Nutr
- M
- International Journal of Molecular Sciences
- International Journal of Environmental Resear...
- Cells,
- Cells,
- Antibiot
-
▼
Μαΐ 28
(52)
- ► Φεβρουαρίου (28)
-
►
2019
(2277)
- ► Δεκεμβρίου (18)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (89)
-
►
2018
(26280)
- ► Δεκεμβρίου (189)
- ► Φεβρουαρίου (6130)
- ► Ιανουαρίου (7050)
-
►
2017
(33948)
- ► Δεκεμβρίου (6715)
- ► Σεπτεμβρίου (6470)
-
►
2016
(4179)
- ► Σεπτεμβρίου (638)
- ► Φεβρουαρίου (526)
- ► Ιανουαρίου (517)
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου